AAAAAA

   
Results: 1-25 | 26-50 | 51-75 | 76-76
Results: 1-25/76
THE NORDIC COMMITMENT - REGIONAL AND INTERNATIONAL COLLABORATION ON PLANT GENETIC-RESOURCES
Authors: HULDEN M LUND B POULSEN GB THORN E WEIBULL J
Citation: M. Hulden et al., THE NORDIC COMMITMENT - REGIONAL AND INTERNATIONAL COLLABORATION ON PLANT GENETIC-RESOURCES, Plant varieties & seeds, 11(1), 1998, pp. 1-13
PACLITAXEL-CISPLATIN VS. PACLITAXEL-CARBOPLATIN IN PREVIOUSLY UNTREATED OVARIAN-CANCER
Authors: NEIJT JP ENGELHOLM SA TUXEN M SORENSEN PG HANSEN M SESSA C DESWART CAM HIRSCH FR WITTEVEEN PO LUND B HANSEN SW PALLE B ROER O VANHOUWELINGEN HC
Citation: Jp. Neijt et al., PACLITAXEL-CISPLATIN VS. PACLITAXEL-CARBOPLATIN IN PREVIOUSLY UNTREATED OVARIAN-CANCER, Annals of oncology, 9, 1998, pp. 312-312
A PHASE-I STUDY OF THE NOVEL ANTRACYCLINE ANALOG MEN-10755 BMS-195615(NAA) IN PATIENTS (PTS) WITH A SOLID TUMOR - PRELIMINARY-RESULTS/
Authors: AAMDAL S DOMBERNOWSKY P WANDERS J CAPRIATI A LUND B
Citation: S. Aamdal et al., A PHASE-I STUDY OF THE NOVEL ANTRACYCLINE ANALOG MEN-10755 BMS-195615(NAA) IN PATIENTS (PTS) WITH A SOLID TUMOR - PRELIMINARY-RESULTS/, Annals of oncology, 9, 1998, pp. 656-656
DOCETAXEL AND CISPLATIN IN METASTATIC UROTHELIAL CANCER - A PHASE-II STUDY
Authors: SENGELOV L KAMBY C LUND B ENGELHOLM SA
Citation: L. Sengelov et al., DOCETAXEL AND CISPLATIN IN METASTATIC UROTHELIAL CANCER - A PHASE-II STUDY, Journal of clinical oncology, 16(10), 1998, pp. 3392-3397
A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF EFFICACY AND TOLERANCE OF MELOXICAM TREATMENT IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE
Authors: LUND B DISTEL M BLUHMKI E
Citation: B. Lund et al., A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF EFFICACY AND TOLERANCE OF MELOXICAM TREATMENT IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE, Scandinavian journal of rheumatology, 27(1), 1998, pp. 32-37
RECOVERY OF BEAT-TO-BEAT VARIATIONS OF QRS
Authors: LUND K CHRISTIANSEN EH LUND B PEDERSEN AK
Citation: K. Lund et al., RECOVERY OF BEAT-TO-BEAT VARIATIONS OF QRS, Medical & biological engineering & computing, 36(4), 1998, pp. 438-444
HOUSING PRIVATIZATION IN EASTERN-EUROPE - CLAPHAM,D, HEGEDUS,J, KINTREA,K, TOSICS,I
Authors: LUND B
Citation: B. Lund, HOUSING PRIVATIZATION IN EASTERN-EUROPE - CLAPHAM,D, HEGEDUS,J, KINTREA,K, TOSICS,I, Journal of social policy, 27, 1998, pp. 429-431
EFFECT OF NASAL SALMON-CALCITONIN ON POSTTRAUMATIC OSTEOPENIA FOLLOWING ANKLE FRACTURE - A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDYIN 24 PATIENTS
Authors: PETERSEN MM LAURITZEN JB SCHWARZ P LUND B
Citation: Mm. Petersen et al., EFFECT OF NASAL SALMON-CALCITONIN ON POSTTRAUMATIC OSTEOPENIA FOLLOWING ANKLE FRACTURE - A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDYIN 24 PATIENTS, Acta orthopaedica Scandinavica, 69(4), 1998, pp. 347-350
LOSS OF BONE-MINERAL OF THE HIP ASSESSED BY DEXA FOLLOWING TIBIAL SHAFT FRACTURES
Authors: PETERSEN MM GEHRCHEN PM NIELSEN PK LUND B
Citation: Mm. Petersen et al., LOSS OF BONE-MINERAL OF THE HIP ASSESSED BY DEXA FOLLOWING TIBIAL SHAFT FRACTURES, Bone, 20(5), 1997, pp. 491-495
A DOUBLE-BLIND, RANDOMIZED TRIAL TO COMPARE MELOXICAM 15 MG WITH DICLOFENAC 100 MG IN THE TREATMENT OF OSTEOARTHRITIS OF THE KNEE
Authors: THE HSG LUND B DISTEL MR BLUHMKI E
Citation: Hsg. The et al., A DOUBLE-BLIND, RANDOMIZED TRIAL TO COMPARE MELOXICAM 15 MG WITH DICLOFENAC 100 MG IN THE TREATMENT OF OSTEOARTHRITIS OF THE KNEE, Osteoarthritis and cartilage, 5(4), 1997, pp. 283-288
ORAL ETOPOSIDE IN ELDERLY PREVIOUSLY UNTREATED OVARIAN-CANCER PATIENTS WITH RESIDUAL DISEASE
Authors: TUXEN MK LUND B HANSEN OP BERTELSEN K HANSEN M
Citation: Mk. Tuxen et al., ORAL ETOPOSIDE IN ELDERLY PREVIOUSLY UNTREATED OVARIAN-CANCER PATIENTS WITH RESIDUAL DISEASE, International journal of gynecological cancer, 7(3), 1997, pp. 213-217
TAXOTERE AND CISPLATIN IN METASTATIC UROTHELIAL CANCER - A PHASE-II STUDY
Authors: SENGELOV L KAMBY C LUND B ENGELHOLM SA
Citation: L. Sengelov et al., TAXOTERE AND CISPLATIN IN METASTATIC UROTHELIAL CANCER - A PHASE-II STUDY, European journal of cancer, 33, 1997, pp. 119-119
SAFETY PROFILE OF GEMCITABINE, A NOVEL ANTICANCER AGENT, IN NONSMALL CELL LUNG-CANCER
Authors: CORTESFUNES H MARTIN C ABRATT R LUND B
Citation: H. Cortesfunes et al., SAFETY PROFILE OF GEMCITABINE, A NOVEL ANTICANCER AGENT, IN NONSMALL CELL LUNG-CANCER, Anti-cancer drugs, 8(6), 1997, pp. 582-587
THE ROLE OF 2ND-LOOK LAPAROTOMY IN THE LONG-TERM SURVIVAL IN OVARIAN-CANCER
Authors: TUXEN MK STRAUSS G LUND B HANSEN M
Citation: Mk. Tuxen et al., THE ROLE OF 2ND-LOOK LAPAROTOMY IN THE LONG-TERM SURVIVAL IN OVARIAN-CANCER, Annals of oncology, 8(7), 1997, pp. 643-648
DOFETILIDE IN PATIENTS WITH LEFT-VENTRICULAR DYSFUNCTION AND EITHER HEART-FAILURE OR ACUTE MYOCARDIAL-INFARCTION - RATIONALE, DESIGN, AND PATIENT CHARACTERISTICS OF THE DIAMOND STUDIES
Authors: CAMM AJ ECHT D PRATT C MEINERTZ T MOLLER M SANDOE E BLOCHTHOMSEN PE AGNER E EGSTRUP K KOBER L TORPPEDERSEN C AURUP P FRIEDRICH T CARLSEN J VIDEBAEK J COLE D JULIAN D WHITEHEAD J ANDERSEN J FAEGERMAN O BAGGER H BAGGER JP STEINMETZ E IBSEN H HANSEN AD SKAGEN K GOTZSCHE CO NIELSEN HV BURCHARDT H SEIBAEK M MARCHANT B HANSEN S KRISTENSEN K GULDAGER T HULD P MUNSTER A ANDERSEN S PEDERSEN O SIBONI A NIELSEN T SAEKMOSE S POULSEN K LINDSKOV J AVER P ANDERSEN HH SORENSEN BK ANDERSEN HA MARKENVARD J HANSEN KN FRANDSEN F HUMBURG K JENSEN AL SOSTED U KNUDSEN BM HOLMGAARD P LYNGBORG K JACOBSEN TJ KRISTENSEN GS SYKULSKI R HILDEBRANDT P RAA D KJAERGAARD J DEPCIK H VESTERGAARD S SONDERGAARD J ORLOWITZ S OLSEN E LARSSON J HANSEN PF MAINZ H MELCHIOR T ELMING H LOEHR D JORGENSEN U BUCHWALD C ROKKEDAL J ZABEL S JORGENSEN A PLESS P BULOW M GAMMELGAARD FJ LUND B KRISTENSEN T ORLOFF P BRANDT D JENSEN SE POULSEN SH FRIIS E MYGIND L MUNK L JENSEN LE RYNNING B RALFKIAER N JORGENSEN H WINTHER M KANTERS J ABILDSTROM SZ WIEMANN O HORNUM L HERLEV KAS NELAND K HOST U GRONNING H THERKELSEN A KLARHOLT E KACZAN M VEJBYCHRISTENSEN H NIEMANN T MOURITSEN E LODAHL DB HAGGER K PEDERSEN F MADSEN J DOMINGUEZ H STEIG B BORRING M PETERSEN EL SEJERSEN H PETERSEN J MORK H JENSEN B JOHANSEN I PETERSEN M HANSEN D FROST J TOUBRO N HANSEN JF JENSEN GVH SORUM C FREDERIKSEN M SAJDIEH A SKOV N MOLGAARD S MEIER K KAISER P BRENDRUP B BLAK AK HOLMGAARD B NIELSEN M JOHANNESEN A LINDBJERG J LARSEN A WULFF B JORGENSEN L SCHEIBEL M HAAHR S LILLOR K FENGER A ASKLUND M BJERRE K GYLDENKERNE N BUHL S FELDTHAUS B METAIS I GARDE K CHRISTENSEN S RASMUSSEN B RASMUSSEN SL NIELSEN G HELO O CHRISTENSEN I LUND B GLUD T MOLLER BB GLESNER P SVENDSEN TL MADSEN H RAYMOND I LARSEN J ELIN P JENSEN BS HINTZE U HAGHFELT T VILLADSEN H THOMSEN KK GANDRUP U ROSENLUND I PAARUP L HALSE J NIELSEN I THORBALL N MOGELVANG J LARSEN I TRUESEN S KJOLLER E HEIBERG J CHRISTIANSEN K DREWES VM STENTEBJERG SE POULSEN J BUHL J LUCKOW A ANDERSEN L KJELDSEN L STENTEBJERG A KRISTENSEN H ELIASEN P LESSING M MAERKEDAL H NORHOLM C NIELSEN M GJORUP T NIELSEN H BRINCH EA SKOV JB HEMPEL H EGEDE F RASMUSSEN OB MARLEY M JENSEN IF PETERSEN J FISHER T THOMSEN NK RIGGELSEN T MARCUSSEN C BRONS M SIMONSEN E ANDERSEN J ANDERSEN B EICHORST R LAURIDSEN M ALBRECHTSEN E DORFF B ANDERSEN HB CALLESEN L DEDING A TANGO M ZEUTHEN E JOHANSEN PB NIELSEN PF MARTINSEN K VIGH L FRANDSEN K LEDERBALLE O NIELSEN HK MALCZYNSKE J RAUNGAARD B NYVAD O BENN M BERG S KRISTENSEN SD GOTZSCHE C SONDERGAARD E SONDERGAARD B LARSEN A HANSEN HT SKRIVER L WESTERGAARD M HANSEN AL BJORN M MUNKSGAARD D BRENDSTRUP C KARLSEN S CARLSEN N HOUE K DEELA C ANDERSEN H KROGSTRUP L PEDERSEN N WENDT N AGERHOLM L ANDERSEN IM JOHANSEN L LUNDBERG S NIELSEN L SNORGAARD M TVESKOV H FRIEDRICH T DALRYMPLE I WHITE S INGAMELLS A ANDREWS G HILTON C KENT C STEADMAN J HART J COE R WARWICK V SMITH K FOWLER G HOLMAN L COE A COMPTON A OAKES L WEARING A JACKSON V NELSON G MCDOWELL P EAST M MCDOWELL L BASI M DONNELLY P NITSCHMAN P SOLCA AM FARBRACE P TREBBLE A SHEPHERD S DIGHT B
Citation: Aj. Camm et al., DOFETILIDE IN PATIENTS WITH LEFT-VENTRICULAR DYSFUNCTION AND EITHER HEART-FAILURE OR ACUTE MYOCARDIAL-INFARCTION - RATIONALE, DESIGN, AND PATIENT CHARACTERISTICS OF THE DIAMOND STUDIES, Clinical cardiology, 20(8), 1997, pp. 704-710
PACLITAXEL (175 MG M(2) OVER 3 HOURS) WITH CISPLATIN OR CARBOPLATIN IN PREVIOUSLY UNTREATED OVARIAN-CANCER - AN INTERIM ANALYSIS/
Authors: NEIJT JP ENGELHOLM SA WITTEVEEN PO TUXEN MK SORENSEN PG HANSEN M HIRSCH F SESSA C DESWART C VANHOUWELINGEN HC LUND B HANSEN SW
Citation: Jp. Neijt et al., PACLITAXEL (175 MG M(2) OVER 3 HOURS) WITH CISPLATIN OR CARBOPLATIN IN PREVIOUSLY UNTREATED OVARIAN-CANCER - AN INTERIM ANALYSIS/, Seminars in oncology, 24(5), 1997, pp. 36-39
PHASE-II TRIAL OF HIGH-DOSE CISPLATIN PLUS IFOSFAMIDE AS FIRST-LINE FOLLOWED BY CARBOPLATIN AS SECOND-LINE TREATMENT IN EPITHELIAL OVARIAN-CARCINOMA
Authors: STRAUSS G LUND B HANSEN M HANSEN HH
Citation: G. Strauss et al., PHASE-II TRIAL OF HIGH-DOSE CISPLATIN PLUS IFOSFAMIDE AS FIRST-LINE FOLLOWED BY CARBOPLATIN AS SECOND-LINE TREATMENT IN EPITHELIAL OVARIAN-CARCINOMA, Gynecologic oncology, 66(1), 1997, pp. 66-70
ROENTGEN STEREOPHOTOGRAMMETRIC ANALYSIS USING COMPUTER-BASED IMAGE-ANALYSIS
Authors: OSTGAARD SE GOTTLIEB L TOKSVIGLARSEN S LEBECH A TALBOT A LUND B
Citation: Se. Ostgaard et al., ROENTGEN STEREOPHOTOGRAMMETRIC ANALYSIS USING COMPUTER-BASED IMAGE-ANALYSIS, Journal of biomechanics, 30(9), 1997, pp. 993-995
COMBINED HIGH-DOSE PLATINUM AND ETOPOSIDE IN PREVIOUSLY UNTREATED OVARIAN-CANCER PATIENTS WITH RESIDUAL DISEASE
Authors: STRAUSS G LUND B HANSEN M HANSEN OP HANSEN HH
Citation: G. Strauss et al., COMBINED HIGH-DOSE PLATINUM AND ETOPOSIDE IN PREVIOUSLY UNTREATED OVARIAN-CANCER PATIENTS WITH RESIDUAL DISEASE, International journal of gynecological cancer, 6(5), 1996, pp. 410-414
QUANTITATIVE PATHOLOGICAL VARIABLES AS PROGNOSTIC FACTORS FOR OVERALLSURVIVAL IN DANISH PATIENTS WITH FIGO STAGE-III OVARIAN-CANCER
Authors: BRINKHUIS M LUND B MEIJER GA BAAK JPA
Citation: M. Brinkhuis et al., QUANTITATIVE PATHOLOGICAL VARIABLES AS PROGNOSTIC FACTORS FOR OVERALLSURVIVAL IN DANISH PATIENTS WITH FIGO STAGE-III OVARIAN-CANCER, International journal of gynecological cancer, 6(3), 1996, pp. 168-174
IN DUTCH AND DANISH PATIENTS WITH FIGO-III OVARIAN-CARCINOMA, GEOGRAPHIC SURVIVAL DIFFERENCES ARE ASSOCIATED WITH DIFFERENCES IN QUANTITATIVE PATHOLOGICAL FEATURES
Authors: BRINKHUIS M BAAK JPA VANDIEST PJ LUND B WILS J
Citation: M. Brinkhuis et al., IN DUTCH AND DANISH PATIENTS WITH FIGO-III OVARIAN-CARCINOMA, GEOGRAPHIC SURVIVAL DIFFERENCES ARE ASSOCIATED WITH DIFFERENCES IN QUANTITATIVE PATHOLOGICAL FEATURES, International journal of gynecological cancer, 6(2), 1996, pp. 108-114
PHASE-I PHARMACOKINETICS AND LIMITED SAMPLING STRATEGIES FOR THE BIOREDUCTIVE ALKYLATING DRUG E09
Authors: MCLEOD HL GRAHAM MA AAMDAL S SETANOIANS A GROOT Y LUND B
Citation: Hl. Mcleod et al., PHASE-I PHARMACOKINETICS AND LIMITED SAMPLING STRATEGIES FOR THE BIOREDUCTIVE ALKYLATING DRUG E09, European journal of cancer, 32A(9), 1996, pp. 1518-1522
GEMCITABINE - ONCE-WEEKLY SCHEDULE ACTIVE AND BETTER TOLERATED THAN TWICE-WEEKLY SCHEDULE
Authors: MARTIN C LUND B ANDERSON H THATCHER N
Citation: C. Martin et al., GEMCITABINE - ONCE-WEEKLY SCHEDULE ACTIVE AND BETTER TOLERATED THAN TWICE-WEEKLY SCHEDULE, Anti-cancer drugs, 7(3), 1996, pp. 351-357
LATE CHANGES IN BONE-MINERAL DENSITY OF THE PROXIMAL TIBIA FOLLOWING TOTAL OR PARTIAL MEDIAL MENISCECTOMY - A RANDOMIZED STUDY
Authors: PETERSEN MM OLSEN C LAURITZEN JB LUND B HEDE A
Citation: Mm. Petersen et al., LATE CHANGES IN BONE-MINERAL DENSITY OF THE PROXIMAL TIBIA FOLLOWING TOTAL OR PARTIAL MEDIAL MENISCECTOMY - A RANDOMIZED STUDY, Journal of orthopaedic research, 14(1), 1996, pp. 16-21
STRUCTURE OF NE-18 AND THE BREAKOUT FROM THE HOT CNO CYCLE
Authors: HAHN KI GARCIA A ADELBERGER EG MAGNUS PV BACHER AD BATEMAN N BERG GPA BLACKMON JC CHAMPAGNE AE DAVIS B HOWARD AJ LIU J LUND B MAO ZQ MARKOFF DM PARKER PD SMITH MS STEPHENSON EJ SWARTZ KB UTKU S VOGELAAR RB YILDIZ K
Citation: Ki. Hahn et al., STRUCTURE OF NE-18 AND THE BREAKOUT FROM THE HOT CNO CYCLE, Physical review. C. Nuclear physics, 54(4), 1996, pp. 1999-2013
Risultati: 1-25 | 26-50 | 51-75 | 76-76